AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04487600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active voiding trial
Study NCT04482725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 3
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Propylene glycol 18.5 mg/mL
Study NCT03520439 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo Oral Tablet 1# (first menstrual third days), 1 times a day, 12 weeks, fasting or taking 2 hours after eating
Study NCT02825433 — intervention group
Intervention type: OTHER
Intervention: No intervention, only ventilation monitoring
Study NCT02789449 — intervention group
Intervention type: OTHER
Intervention: assessment of DLNO and DLCO
Study NCT04482725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 4
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Glycerol 22.0 mg/mL
Study NCT05808114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU
Description: Individually tailored and delivered specialized child psychiatric care
Study NCT04482725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 5
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Mannitol 44.0 mg/mL
Study NCT02116946 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (PRP)
Description: Injection of Leukocyte-rich or Leukocyte-poor Platelet Rich Plasma prepared by the Angel cPRP System along with a 12 week exercise program for treatment of patients with patellar tendinopathy.
Study NCT02116946 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline + exercise
Description: Peritendinous saline injection plus 12 week exercise program.
Study NCT03021070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditional cash transfer
Description: For each honoured and verified health visit that is made on time following enrollment, a woman receives a cash transfer. The value reduces by one quarter for each week of delayed visit, and no reward is offered for any visit made 3 weeks after the appointment date. Transportation cost by a local taxi to the health facility, and is a value that has been approved by the research ethics committee for many studies in the region as reasonable compensation for research participants.
Study NCT02151110 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4920 3 mg
Description: Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.
Study NCT02151110 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4920 10 mg
Description: Participants received single IV dose of MEDI4920 10 mg infused on Day 1.
Study NCT02151110 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4920 30 mg
Description: Participants received single IV dose of MEDI4920 30 mg infused on Day 1.
Study NCT02151110 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4920 100 mg
Description: Participants received single IV dose of MEDI4920 100 mg infused on Day 1.
Study NCT02151110 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4920 300 mg
Description: Participants received single IV dose of MEDI4920 300 mg infused on Day 1.
Study NCT02151110 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4920 1000 mg
Description: Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.
Study NCT02151110 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4920 3000 mg
Description: Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.
Study NCT04482725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 6
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Sucrose 82.0 mg/mL
Study NCT02151110 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.
Study NCT00850590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001
Description: Four single doses of NRL001 or placebo. NRL001 is administered at lower (5, 7.5 and 10 mg) or higher (10, 12.5 and 15 mg) doses in a slow release rectal suppository weighing either 1 g or 2 g.
Study NCT02398760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Control Exercises
Description: Subjects performed 8 weeks of motor control exercises intervention, 2 weekly 1 hour per session, instructed by trained physiotherapists to apply this program following a protocol developed in programs previously reported (Costa et al. 2009; Hodges et al. 2009). The first stage aims to improve the activity of muscles that have poor control and reduce overactivity of superficial muscles, previously assessed, through drawing in maneuver with feedback real-time ultrasound and via palpation. The second stage of the treatment involved more functional exercises, first using static and then dynamic tasks.
Study NCT04719286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MinSafeStart app
Description: The intervention is the opportunity of using the MinSafeStart app. Women can register their NVP severity in the app by answering a few questions daily. Based on this, they will get tailored advice on NVP, and get alert when they should see a doctor.
Study NCT03217812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velcade
Description: Participants will receive velcade 1.3 mg/m\^2, SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9 of Treatment Arm A and B.
Study NCT03217812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Participants will receive velcade 1.3 mg/m\^2, SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9 of Treatment Arm A and B.
Study NCT03217812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Participants will receive melphalan 9 mg/m\^2 (if serum creatine is >2 mg/dL at baseline, participants must be administrated 4.5 mg/m\^2 of melphalan, instead of 9 mg/m\^2), orally, once daily on Days 1 to 4 of each cycle up to Cycle 9 Treatment Arm A and B.
Study NCT03217812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Participants will receive melphalan 9 mg/m\^2 (if serum creatine is >2 mg/dL at baseline, participants must be administrated 4.5 mg/m\^2 of melphalan, instead of 9 mg/m\^2), orally, once daily on Days 1 to 4 of each cycle up to Cycle 9 Treatment Arm A and B.
Study NCT04482725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 7
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: a,a-Trehalose, dihydrate 90.0 mg/mL
Study NCT03217812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Participants will receive prednisone 60 mg/m\^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9 Treatment Arm A and B.
Study NCT03217812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will receive prednisone 60 mg/m\^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9 Treatment Arm A and B.
Study NCT04482725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 8
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 5.34 mg/mL Isotonic agent: NaCl 6.72 mg/mL
Study NCT04482725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 9
Description: Buffering agent: Tris 2.4 mg/mL Isotonic agent: Propylene glycol 19 mg/mL
Study NCT03217812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Participants will receive daratumumab 16 mg/kg as IV infusion or daratumumab SC, once weekly, for 6 weeks in Cycle 1 and then once every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or the end of study in Treatment Arm B.
Study NCT02721485 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ringer's Lactate
Description: After a 1 week run in half of participating hospitals will be crossed over to using Ringer's Lactate as 500 or 1000 ml boluses or infusions as specified by the treating physicians for the second 90-day test period.
Study NCT02721485 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Normal Saline
Description: After a 1 week run in half of participating hospitals will be crossed over to using Normal Saline as 500 or 1000 ml boluses or infusions as specified by the treating physicians for the final 90-day test period.
Study NCT00827333 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Family Caregiver Palliative Care Intervention at weeks 7, 8, 10, and 12 post study enrollment
Study NCT00827333 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
Study NCT00827333 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: end-of-life treatment/management
Description: Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
Study NCT00827333 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: psychosocial assessment and care
Description: Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
Study NCT04482725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 10
Description: Buffering agent: Glutamic acid 0.74 mg/mL Isotonic agent: Glycerol 24.0 mg/mL
Study NCT01918787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive TMS
Description: rTMS (intermittent theta burst stimulation 1200)over posterior superior temporal sulcus,dorsolateral prefrontal cortex and inion as Sham control
Study NCT04260919 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy
Study NCT05485259 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DL-alpha lipoic acid
Description: Treatment group recieves 600 mg of DL-alpha lipoic acid daily, per os, for 3 months.
Study NCT05485259 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo (rice starch)
Description: Placebo group recieves 600 mg (2x300 mg) of placebo (rice starch) daily, per os, for 3 months
Study NCT03216083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Injectable Solution
Description: 1g IV tranexamic acid mixed in normal saline (67mL)
Study NCT03216083 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 67mL IV normal saline
Study NCT00854555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Locomotor training with robot
Description: 60 days locomotor training during 6 months period in out-patient setting. Minimum 60 min training up to 3 times per week. Control group receives conventional training/treatment.
Study NCT00854555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Locomotor training with manual assistance
Description: 60 days training during 6 months period on in-patient setting. Training 2 times per day total 120 minutes. Control group receives conventional training/treatment.
Study NCT02746848 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amniotic Membrane Extract Eye Drop
Description: Amniotic Membrane Extract use as eye drop for patients with corneal injury.
Study NCT02293096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol succinate
Study NCT02293096 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genotyping
Description: CYP2D6 only clinically pertinent pathway of metoprolol metabolism and polymorphisms have been associated with altered levels of metoprolol. ADRB1 is the drug target and polymorphism in this receptor has been associated with variable drug response. Genotyping will occur after the treatment phase is complete. Thus the investigator, the subject, and the outcomes investigator will be blind to the intervention.
Study NCT02293096 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CYP2D6 Phenotyping
Description: Phenotype can be discordant from what is predicted by genotype due to variability in absorption, hepatic blood flow, drug interaction and drug elimination. These factors can be accounted for by utilizing a phenotyping assay that determines area under the curve of the probe since the probe is affected by the same variables dictating metabolism phenotype of the therapeutic drug. Investigators will be blind to the patient blood pressure outcome for this intervention.
Study NCT01852695 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Integrated Care
Description: Parents are integrated into the care of their infants in the NICU. Parents consent to spending up to eight hours a day with their infant, attend special education sessions, participate in daily medical rounds, and do basic infant charting. This will enable parents to provide care for infants with nursing supervision in the areas of feeding, bathing, dressing and holding skin to skin.
Study NCT01750944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ankle first
Description: 1. Brachial blood pressure on both the left and right (BBP-LR) sides is measured, as well as at the left and right ankles (BPA-LR).~2. A 15 minute walking test (WT) is performed.~3. BBP-LR and BPA-LR are re-measured.~4. 2 hours of rest.~5. BBP-LR and the blood pressure at the left and right big toes (BPT-LR) are measured.~6. WT is reperformed.~7. BBP-LR and BPT-LR are re-measured.
Study NCT01750944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Toe first
Description: 1. Brachial blood pressure on both the left and right (BBP-LR) sides is measured, as well as at the left and right big toes (BPT-LR).~2. A 15 minute walking test (WT) is performed.~3. BBP-LR and BPT-LR are re-measured.~4. 2 hours of rest.~5. BBP-LR and the blood pressure at the left and right ankles (BPA-LR) are measured.~6. WT is reperformed.~7. BBP-LR and BPA-LR are re-measured.
Study NCT00827333 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
Study NCT04482725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 10
Description: Buffering agent: Sodium Acetate, trihydrate 0.68 mg/mL Isotonic agent: Glycerol 24.0 mg/mL
Study NCT01995812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hula and heart health education
Study NCT00742807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of alfentanil hydrochloride
Description: Administration of low dose alfentanil hydrochloride before paracervical block
Study NCT00742807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal dose of alfentanil hydrochloride
Description: Normal dose of alfentanil hydrochloride is administered after paracervical block
Study NCT00185354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-5016, SH P00331F
Description: Drug amount per patch: 0.9 mg EE2 + 1.9 mg gestodene (GSD)
Study NCT00185354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SH P00331N
Description: Drug amount per patch: 0.6 mg EE2 + 6 mg NGM
Study NCT00965146 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scorpio® CR Total Knee System
Description: All subjects will be implanted with a femoral component, a tibial insert, a tibial tray and a resurfaced patella.
Study NCT00227994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: Participants assigned to receive galantamine will receive 4 mg twice a day for 4 weeks, 8 mg twice a day for the next 4 weeks, and 12 mg twice a day for the remainder of the study.
Study NCT00227994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Participants assigned to receive donepezil will receive 5 mg twice a day for 6 weeks, and then 10 mg twice a day for the next 6 weeks.
Study NCT04482725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 12
Description: Buffering agent: Glutamic acid 0.46 mg/mL, Disodium hydrogen phosphate, dihydrate 2.00 mg/mL Isotonic agent: Glycerol 15 mg/mL, NaCl 2.5 mg/mL
Study NCT01150383 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercise training with supplemental oxygen
Description: Prior to the exercise training, an intervention-free control period with usual care is planned.~Intervention group with oxygen supplementation: Endurance training (performed within 70-80% of the heart rate at the anaerobic threshold) as well as strength training will be performed with oxygen supplementation.~After 6 weeks of intervention with oxygen supplementation, second intervention period will start with room air instead of oxygen supplementation (as described above).
Study NCT01150383 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercise training with room air supplementation
Description: Prior to the exercise training, an intervention-free control period with usual care is planned.~Intervention group with room air supplementation: Endurance training (performed within 70-80% of the heart rate at the anaerobic threshold) as well as strength training will be performed under normoxic conditions.~After 6 weeks of intervention with room air, second intervention period will start with oxygen supplementation instead of room air (as described above).
Study NCT05680389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 100 mg twice daily for 3 months
Study NCT05680389 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily for 3 months
Study NCT02890277 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the high intensity focused ultrasound (Mianyang Sonic electronic LLC)
Study NCT00904995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Starting dose of 400 mg by mouth twice a day for first day, followed by 200 mg by mouth twice a day thereafter.
Study NCT02890277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fu Tiankang disposable vaginal filling suppository, Albothyl (Policresulen Solution) , and the gynecologic medical antimicrobial dressing gel (chitosan gel).
Study NCT03289143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semorinemab
Description: Participants will receive Semorinemab intravenously (IV).
Study NCT03289143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo doses of Semorinemab given intravenously (IV).
Study NCT03289143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]GTP1
Description: \[18F\]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.
Study NCT03289143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: [18F]GTP1
Description: \[18F\]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.
Study NCT02117778 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Nerve Block
Study NCT03334838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifurtimox (Lampit, BAYA2502)
Description: Oral Intake of 4 x 30 mg nufurtimox tablets for treatment A-D; Oral Intake of 8 x 30 mg nufurtimox tablets for treatment E.
Study NCT02777086 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: StaySafe
Description: StaySafe is a self-administered tablet computer app designed to improve decision-making around health risk behaviors.
Study NCT04407338 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B-DYN
Description: The surgical technique for placement of the B-Dyn device is performed under general anaesthesia. The procedure begins with the insertion of the first upper polyaxial screw which is screwed in with the polyaxial screwdriver. The use of the phantom (Trial 10) is necessary in order to position the second screw. Once the screws are positioned, the B-Dyn is taken between the jaws of the gripping forceps in order to insert it into the heads of the polyaxial screws. The movable rod of the B-Dyn is then placed in the head of the upper screw. The positioning mark of the fixed rod must be placed facing the operator and in the center of the lower screw head. Finally the cap of the lower polyaxial pedicle screw is tightened. A final tightening of the two plugs on the polyaxial pedicle screw heads is performed to fix the assembly.
Study NCT04407338 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Bolted fusion (with or without cage)
Description: The surgeon will complete his gesture by placing 2 screws in the upper vertebra and 2 screws in the lower vertebra; the screws will be connected to each other to stabilize the assembly. This type of surgery is done via posterior approach and under general anaesthesia.
Study NCT01508208 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hypertensive disorder of pregnancy
Description: Collection of a random sample of urine for a spot test and a 24 hour urine collection for a 24 hour urine protein.
Study NCT04441697 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multiple sleep latency tests
Description: The investigators measure the objective sleepiness by recording the electro-encephalogramm during four experimental diurnal naps. They also perform a nocturnal polysomnography prior to the tests for a better interpretation.